by barry-jtcir | Oct 7, 2024 | Press Releases
LA JOLLA, CA, Oct. 07, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
by barry-jtcir | Sep 30, 2024 | Press Releases
Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
by barry-jtcir | Sep 26, 2024 | Press Releases
MHRA and HREC authorization in Australia further expands and will potentially accelerate enrollment in ongoing U.S. and UK Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Company on track...
by barry-jtcir | Sep 25, 2024 | Press Releases
Live video webcast on Wednesday, October 2nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative...
by barry-jtcir | Sep 18, 2024 | Press Releases
Albert Agro, PhD, CMO of GRI Bio recently participated in a Virtual Investor KOL Connect segment with prominent key opinion leader in Idiopathic Pulmonary Fibrosis (IPF) – Dr. Helen Parfrey, Respiratory Consultant at the Royal Papworth Hospital and Affiliated...
by barry-jtcir | Sep 5, 2024 | Press Releases
LA JOLLA, CA, Sept. 05, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
